This suggests that more PRH patients could potentially benefit from HER2‐targeted therapies, especially considering that ERBB2 amplification identified through NGS of tissue DNA or circulating cell‐free DNA is increasingly recognized as a reliable biomarker for predicting the efficacy of HER2‐targeted therapies in GC [83, 84] and other cancers, where it has been shown to correlate with better responses to trastuzumab, further emphasizing the clinical relevance of CNA assessment in this population [73]. This evidence concerns the gene ERBB2 and gastric cancer.